Botulinum toxin useful therapeutic option to improve cutaneous flushing, finds study

Cutaneous flushing is a common dermatologic concern often resistant to conventional treatments.Oral medication or light-based therapies including laser or intense pulsed therapy may not be effective in some cases of persistent erythema and flushing. Intradermal botulinum toxin A (BTX-A) injection can be used to treat intractable erythema and flushing, but studies with large samples and long-term observation have not been conducted to determine its effectiveness and safety. 

A new research suggests that botulinum toxin, known for its diverse therapeutic applications, may offer relief for flushing symptoms. This study was aimed to evaluate the efficacy of botulinum toxin in treating cutaneous flushing.

This study was published in the journal of Dermatologic Surgery by Vincent and colleagues. A systematic review of databases including Medline, Embase, Cochrane CENTRAL, CINAHL, Scopus, and Web of Science was conducted to identify studies assessing the effect of botulinum toxin on flushing. Prespecified outcome measures included clinical flushing score, dermatology life quality index (DLQI), and erythema index (EI).

Meta-analysis was performed to calculate mean differences in these outcomes before and after botulinum toxin treatment at 1-month follow-up.

  • Nine studies involving 132 patients were included in the analysis, comprising 2 randomized controlled trials and 7 nonrandomized studies.

  • All studies demonstrated a low risk of bias, indicating high quality.

  • The meta-analysis revealed a significant decrease in clinical flushing scores by 1.25 points overall (95% confidence interval [CI]: −2.47; −0.04) 1 month after botulinum toxin treatment.

  • Mean DLQI scores improved by 9.02 points (95% CI: −19.81; 1.77) following botulinum toxin injections.

  • Although the EI (measured by Mexameter) showed improvement in 2 studies, statistical analysis was inconclusive due to insufficient data.

This meta-analysis provides evidence that botulinum toxin effectively reduces clinical flushing scores 1 month after treatment. This finding underscores the potential of botulinum toxin as a therapeutic option for managing cutaneous flushing, offering hope for individuals with this challenging dermatologic condition.

Reference:

Vincent, N., Ravipati, A., Reynolds, J. M., & Kaufman, J. (2024). Efficacy of botulinum toxin in the treatment of cutaneous flushing: A systematic review and meta-analysis. Dermatologic Surgery, 10.1097/DSS.0000000000004073. https://doi.org/10.1097/dss.0000000000004073

Powered by WPeMatico

BC RRM-F Promising Alternative to Gold Standard MTA for primary molar pulpotomy, reveals Pediatric Dentistry Study

In a groundbreaking development for pediatric dentistry, researchers have explored an alternative to the long-established gold standard material, Mineral Trioxide Aggregate (MTA), for vital pulpotomy procedures in primary molars. The study concludes that TotalFill® BC RRM™ Fast Set Putty can be considered a viable alternative to MTA for primary molar pulpotomy.

The study results were published in the Journal of Dentistry. 
Mineral Trioxide Aggregate (MTA) has long been hailed as the gold standard material for pulpotomy procedures in pediatric dentistry. However, challenges related to poor handling and extended setting times have prompted a quest for alternatives. Hence, researchers conducted a recent double-blinded, randomized controlled trial, to compare the radiographic and clinical performance of a premixed, fast-setting bioceramic root repair material (BC RRM-F) with MTA in vital pulpotomy procedures for primary molars in children. The study also explored the impact of different restorative materials, namely stainless-steel crowns (SSC) and glass ionomer (GI), on the success of these procedures.
Conducted as a double-blinded, four-arm, parallel group randomized controlled trial, the study involved 64 primary molars. These were strategically allocated to four treatment groups: MTA with a stainless steel crown (SSC), MTA with glass ionomer (GI), BC RRM-F with GI, and BC RRM-F with SSC. The primary objective was to compare the radiographic and clinical performance of BC RRM-F with MTA, providing valuable insights into the efficacy of these materials in pulpotomy procedures for children.Methods:
Clinical and radiographic evaluations were conducted at intervals of 1, 3, 6, and 12 months, employing the modified Zurn and Seale criteria. Multivariate Cox regression models and Kaplan-Meier curves were utilized for survival analysis, offering a comprehensive understanding of the long-term impact of the tested materials.
Results:
  • Contrary to the longstanding belief in MTA as the gold standard, the study revealed that TotalFill® BC RRM™ Fast Set Putty can serve as a credible alternative in primary molar pulpotomy procedures.
  • The research found no statistically significant difference in the success rates of pulpotomy procedures between MTA and BC RRM-F.
  • Moreover, the choice of final restorative material proved to be a crucial factor.
  • Survival analysis indicated that using glass ionomer (GI) instead of stainless-steel crowns (SSC) was associated with an increased risk of failure, emphasizing the significance of the overall treatment approach.
The study’s findings pave the way for a paradigm shift in pediatric dentistry, suggesting that BC RRM-F holds promise as an effective substitute for MTA in vital pulpotomy procedures. Notably, the research underscores the importance of considering both clinician preferences and cost-effectiveness when choosing between these materials. Clinicians are urged to take a holistic approach, weighing factors such as preference, cost, and parental expectations when deciding between MTA and BC RRM-F for primary molar pulpotomy. The study also highlights the nuanced considerations related to parental preferences for tooth-colored restorations, providing valuable insights for enhancing patient care and satisfaction in pediatric dentistry. This research opens up new possibilities for optimizing treatment approaches, ensuring that children receive the most effective and well-suited interventions based on individual needs and preferences.

Further reading: One-year Radiographic and Clinical Performance of Bioactive Materials in Primary Molar Pulpotomy: A Randomized Controlled Trial. Doi: https://doi.org/10.1016/j.jdent.2024.104864

Powered by WPeMatico

Is surgery the best option for ruptured Achilles tendons in young adults?

There continues to be debate regarding the optimal treatment of acute Achilles tendon rupture (ATR). Over the past 15 years, a growing number of studies have compared nonoperative vs operative treatment of ATR, providing clinicians with estimates of treatment success and complication rates for these approaches. 

An Achilles tendon rupture typically means surgery for many patients.

A research team led by Laurence Ge, M.D., an orthopaedic surgery resident mentored by Paul Talusan, M.D. at University of Michigan Health looked at the difference in outcomes of those treated with and without surgical procedures for their Achilles tendon ruptures in young adults.

While surgical Achilles tendon repairs reattach the torn tendon to help the torn pieces fuse together again, there is a rehab protocol that can avoid surgery. This protocol involves the patient flexing their foot down to help bring the pieces of the tendon close together during scarring, creating the same effect a surgical procedure would have.

The study looked at patients between the ages of 18 and 30 who are not athletes to assess their outcomes from both types of treatment for ruptured Achilles tendons.

“Patients under 30 years of age will typically receive a surgical repair when their Achilles tendon is ruptured due to being more physically active,” said Ge.

“However, our research showed that there is little difference between surgical repair and rehabbing the ruptured Achilles tendon when it comes to ability to function.”

The findings provide more treatment options for these patients.

“We hope that this will help reassure patients and physicians about the outcomes of non-surgical repairs for ruptured Achilles tendons,” said Ge.

“Regardless, it is always important to discuss with your physician what is best for you when it comes to these types of injuries.”

Reference:

Ge L, Saunders N, Betts D, Holmes JR, Walton DM, Talusan PG. Midterm Outcomes of Operatively and Nonoperatively Managed Achilles Tendon Ruptures in Young Adults. Foot Ankle Orthop. 2023 Sep 26;8(3):24730114231198849.

doi: 10.1177/24730114231198849

Powered by WPeMatico

Tomato juice consumption can help eliminate typhoidal Salmonella and improve digestive health: Study

USA: A new study published in Microbiology Spectrum has shed light on the antimicrobial properties of tomato juice and peptides against typhoidal Salmonella. 

The research revealed that tomato juice demonstrates significant antimicrobial properties against Salmonella Typhi, a deadly human-specific pathogen that specifically affects humans and is responsible for causing typhoid fever. 

“Tomato juice can kill Salmonella Typhi and other bacteria that can harm people’s digestive and urinary tract health,” the researchers reported. 

“Our main goal in this study was to find out if tomato and tomato juice can kill enteric pathogens, including Salmonella Typhi, and if so, what qualities they have that make them work,” said principal study investigator Jeongmin Song, Ph.D., Associate Professor, Department of Microbiology & Immunology, Cornell University.

First, the researchers, in laboratory experiments, checked to see if tomato juice really does kill Salmonella Typhi. Once they ascertained it did, the team looked at the tomato’s genome to find the antimicrobial peptides that were involved. Antimicrobial peptides are very small proteins that impair the bacterial membrane that keep them as intact organisms. The researchers chose 4 possible antimicrobial peptides and tested how well they worked against Salmonella Typhi. This helped them find 2 antimicrobial peptides effective against Salmonella Typhi.

The research team conducted more tests on Salmonella Typhi variants that appear in places where the disease is common. They also did a computer study to learn more about how the antibacterial peptides kill Salmonella Typhi and other enteric pathogens. Lastly, they looked at how well tomato juice worked against other enteric pathogens that can hurt people’s digestive and urinary tract health.

The most significant discovery is that tomato juice is effective in eliminating Salmonella Typhi, its hypervirulent variants, and other bacteria that can harm people’s digestive and urinary tract health. In particular, 2 antimicrobial peptides can eliminate these pathogens by impairing the bacterial membrane, a protective layer that surrounds the pathogen.

“Our research shows that tomato and tomato juice can get rid of enteric bacteria like Salmonella,” Song said. The researchers said they hope that when the general public, particularly children and teenagers, learns about the study outcome, they will want to eat and drink more tomatoes as well as other fruits and vegetables because they provide natural antibacterial benefits to consumers.

Reference:

Ryan S. Kwon, Gi Young Lee, Sohyoung Lee, Jeongmin Song. Antimicrobial properties of tomato juice and peptides against typhoidal Salmonella. Microbiology Spectrum, 2024; DOI: 10.1128/spectrum.03102-23.

Powered by WPeMatico

Maternal Folic Acid Supplementation may mitigate Kawasaki Disease risk in infants, unravels study

In a groundbreaking cohort study
conducted by the Japan Environment and Children’s Study, researchers have
discovered a potential link between maternal folic acid levels and the onset of
Kawasaki disease in infants. The study found that the quantity and timing of folic acid supplementation plays a
pivotal role in mitigating the risk of Kawasaki disease in infants.

The
study results were published in the journal JAMA Network Open.

Kawasaki disease is a form of acute
systemic vasculitis primarily observed in infants and young children. Despite
extensive research, definitive risk factors for this condition remain elusive.
However, there has been previous speculation about a potential link between
maternal folic acid supplementation and the occurrence of Kawasaki disease.
Hence, researchers conducted a study to investigate
the associations of exposure to maternal serum folic acid levels and maternal
folic acid supplementation with the onset of Kawasaki disease during infancy
among offspring.


The study, utilizing data from a
nationwide birth cohort since 2011, analyzed information from 87,702 children
followed up to 12 months of age. Of this population, 336 children were
diagnosed with Kawasaki disease. The key focus of the investigation was on
maternal serum folic acid levels during the second and third trimesters and the
frequency of folic acid supplementation during the entire pregnancy.

The primary outcome was to measure the
onset of Kawasaki disease in offspring up to age 12
months.


Findings:

  • Mothers who took folic acid
    supplements, accounting for 35.7% of the study population with a mean age of 32
    years, exhibited higher serum folic acid levels compared to non-supplementing
    counterparts.


  • Strikingly, the study found that
    higher maternal serum folic acid levels (≥10 ng/mL) were associated with a
    significantly lower risk of Kawasaki disease in offspring compared to lower
    levels (0.27% vs 0.41%; Odds Ratio [OR] 0.68).

  • The findings also pointed to the
    timing of maternal folic acid supplementation.
  • While supplementation during the
    first trimester showed a trend toward a lower prevalence of Kawasaki disease,
    the results were not statistically significant (0.34% vs 0.42%; OR 0.83; 95% CI
    0.66-1.04).
  • However, supplementation during the
    second and third trimesters demonstrated a significant reduction in the risk of
    Kawasaki disease (0.30% vs 0.43%; OR 0.73; 95% CI 0.57-0.94). 

  • These results suggest that not only
    the quantity but also the timing of folic acid supplementation plays a crucial
    role in mitigating the risk of Kawasaki disease in infants.

The study provides
valuable insights into preventive measures for this potentially serious
condition.

The study contributes to the growing
body of evidence on the benefits of folic acid supplementation during
pregnancy. With Kawasaki disease affecting a notable number of infants, these
findings could have far-reaching implications for maternal healthcare
guidelines, emphasizing the need for adequate folic acid intake during specific
trimesters to safeguard infant health.

Further reading: Fukuda S, Tanaka S, Kawakami C, Kobayashi T, Ito S, Japan Environment and Children’s Study Group. Maternal Serum Folic Acid Levels and Onset of Kawasaki Disease in Offspring During Infancy. JAMA Netw Open. 2023;6(12):e2349942. doi:10.1001/jamanetworkopen.2023.49942

Powered by WPeMatico

Accelerated Physical Activity Found to Shield Older Women from Heart Failure in new study

In a bid to enhance public health in
the 21st century, the spotlight is now on preventing heart failure (HF), and a
groundbreaking study sheds light on a potentially transformative approach. The
Objective Physical Activity and Cardiovascular Health (OPACH) in Older Women
study, conducted from March 2012 to April 2014, reveals a compelling link
between accelerometer-measured physical activity (PA), sedentary time, and
incident HF in older women, offering insights into HF subtypes—preserved
ejection fraction (HFpEF) and reduced ejection fraction (HFrEF).


The study results were published in
the journal JAMA Cardiology.

Heart failure (HF) poses a significant
challenge for the aging US population, especially impacting women, older
adults, and diverse groups. The lack of clear therapies for preserved EF
(HFpEF) underscores the importance of HF prevention. The Objective Physical
Activity and Cardiovascular Health (OPACH) study aims to address these gaps,
utilizing accelerometer-measured physical activity to explore associations with
incident overall HF, HFpEF, and HFrEF in older women. The study’s hypothesis
suggests that higher physical activity levels are associated with reduced HF
risk, while increased sedentary time correlates with higher HF risk.


The cohort, consisting of 5951 women
aged 63 to 99 years without known HF, embarked on a seven-day journey with
hip-worn triaxial accelerometry. Follow-up for incident HF extended through
February 2022, unraveling a wealth of data and associations.

The study, analyzing various facets of
daily PA such as total, light, and moderate to vigorous PA (MVPA), along with
steps taken, and sedentary behavior including total sedentary time and mean
bout duration, delivers nuanced insights into HF prevention.


Findings:


  • Among the racially and ethnically
    diverse cohort—comprising non-Hispanic Black, Hispanic, and non-Hispanic White
    women—407 HF cases surfaced during an average follow-up of 7.5 years, with 257
    classified as HFpEF and 110 as HFrEF.
  • The study’s fully adjusted hazard
    ratios (HRs) underscore the impact of physical activity on HF prevention.

  • A 1-standard deviation increment in
    minutes per day of total PA yielded striking HRs of 0.85 (95% CI, 0.75-0.95)
    for overall HF, 0.78 (95% CI, 0.67-0.91) for HFpEF, and 1.02 (95% CI,
    0.81-1.28) for HFrEF.

  • Steps per day and total sedentary time
    also exhibited significant associations with HF subtypes.


  • The study’s cubic spline curves paint
    a vivid picture, emphasizing the significance of total PA and steps per day.
  • An inverse relationship is evident,
    indicating that increased physical activity correlates with a decreased risk of
    overall HF and HFpEF.

  • Conversely, total sedentary time
    showed a positive association, underlining the potential risks of prolonged
    inactivity.


  • Light PA and MVPA emerged as champions
    in the fight against HF, showcasing inverse associations with overall HF and
    HFpEF.

This underscores the role of various intensities of physical activity in
preventing heart failure among older women.

These findings carry profound
implications, suggesting that a strategic focus on increasing physical activity
and reducing sedentary time could serve as a formidable strategy for primary
HFpEF prevention. As discussions surrounding heart failure prevention gain
momentum in public health, this study provides actionable insights that could
significantly impact cardiovascular resilience and foster healthy aging among
older women.

Further reading: LaMonte MJ, LaCroix AZ, Nguyen S, et al. Accelerometer-Measured Physical Activity, Sedentary Time, and Heart Failure Risk in Women Aged 63 to 99 Years. JAMA Cardiol. Published online February 21, 2024. doi:10.1001/jamacardio.2023.5692

Powered by WPeMatico

Enavogliflozin Shows Superior Glucose-Lowering Power in Patients with Renal Impairment: Study

In a significant stride toward more
effective diabetes management, a newly developed SGLT-2 inhibitor,
enavogliflozin, has demonstrated remarkable efficacy in a pooled analysis of two-phase
III trials. The study, focusing on patients with type 2 diabetes mellitus based
on kidney function, reveals compelling insights into enavogliflozin’s
superiority over the well-known dapagliflozin.


The study results were published in
the journal Cardiovascular Diabetology.

Researchers conducted an extensive
analysis, pooling data from 470 patients who participated in two 24-week,
randomized, double-blind trials. The trials aimed to evaluate the efficacy and
safety of enavogliflozin (0.3 mg/day) in comparison to dapagliflozin (10
mg/day). Notably, the subjects were categorized based on their level of kidney
function, distinguishing between mildly reduced and normal estimated glomerular
filtration rate (eGFR).

Data from 470 patients were included
in the analysis, with 235 receiving enavogliflozin (0.3 mg/day) and 235
receiving dapagliflozin (10 mg/day). The patients were categorized based on
mildly reduced (60 ≤ eGFR < 90 mL/min/1.73 m², n = 247) or normal eGFR (≥ 90
mL/min/1.73 m², n = 223).


Results:


  • In the mildly reduced eGFR group,
    enavogliflozin demonstrated a significantly greater reduction in adjusted mean
    change of HbA1c and fasting plasma glucose levels at week 24 compared to
    dapagliflozin (-0.94% vs. -0.77%, P = 0.0196).
  • Notably, the glucose-lowering effect
    of enavogliflozin was more pronounced when combined with dipeptidyl peptidase-4
    inhibitors.

  • Enavogliflozin exhibited potent blood
    glucose-lowering effects regardless of renal function.

  • Conversely, dapagliflozin displayed diminishing
    efficacy with decreasing renal function.


  • Enavogliflozin showcased a higher
    urinary glucose excretion rate in both patient groups.
  • Additionally, the homeostatic model
    assessment revealed a marked decrease in insulin resistance with
    enavogliflozin.

  • Blood pressure, weight loss, and
    homeostasis model assessment of beta-cell function values did not significantly
    differ between enavogliflozin and dapagliflozin.

  • Adverse events were comparable
    between the two drugs.


The study concludes that
enavogliflozin’s glucose-lowering efficacy surpasses that of dapagliflozin,
particularly in patients with type 2 diabetes and mild renal function
impairment. This superiority is attributed to enavogliflozin’s potent urinary
glucose excretion-promoting ability. The emergence of such robust SGLT-2
inhibitors holds promise as an attractive option for patients with inadequate
glycemic control and decreased renal function.

Further reading: Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials. Doi: https://doi.org/10.1186/s12933-024-02155-9

Powered by WPeMatico

Prescription Opioids Linked to Increased Fall Risks among elderly, study finds

In a significant revelation, a recent population-based cohort
study conducted in New South Wales, Australia, has uncovered concerning
associations between prescription opioid analgesics and an elevated risk of
serious falls, particularly among older adults. The
study’s findings suggest that prescription opioids are associated with an
increased risk of serious fall events among adults of all ages, with the
greatest risk observed in individuals aged 85 or older. The
study, designed to explore the age-related risk of serious fall events
associated with opioid use, delves into the nuances of opioid exposure, time
from initiation, and daily dosage.


The study results were published in the journal JAMA Internal
Medicine.

The primary objective of the study was to unravel the intricate
web of associations between prescription opioids and serious fall events.
Researchers aimed to provide a comprehensive perspective by analyzing these
associations across various age groups, shedding light on temporal patterns and
dosage-dependent risks associated with the use of prescription opioids.

Harnessing data that linked national pharmaceutical claims to
diverse datasets encompassing sociodemographic information, clinical
characteristics, medication use, healthcare utilization, and mortality records,
the study included adults aged 18 and older who initiated prescription opioid
treatment between 2005 and 2018.


Revealing Findings:

  • The cohort, consisting of 3,212,369 individuals, witnessed a
    total of 506,573 serious fall events, including 5,210 fatal falls.

  • Strikingly, the study illuminated that the risk of serious fall
    events was heightened across all age groups during exposure to opioids.

  • Notably, individuals aged 85 or older faced the highest risk,
    with an adjusted incident rate ratio of 6.35 in comparison to those aged 18 to
    44.


  • Temporal analysis revealed a critical period within the first 28
    days following opioid initiation, marked by an increased risk of serious falls.
  • This risk, the study found, escalated with age.

  • Additionally,
    for individuals aged 18 to 84, there was a discernible correlation between
    higher daily opioid doses and the occurrence of serious fall events.

  • The study’s findings prompt a reconsideration of opioid
    prescription practices, emphasizing the imperative need for healthcare
    providers to carefully weigh the risks and benefits of prescribing opioids,
    particularly in older populations.

The critical window of the initial month
following opioid initiation emerged as a pivotal period, urging targeted fall
prevention efforts during this timeframe.

The study advocates for a holistic approach to patient care,
prioritizing safety, especially among vulnerable populations.

As prescription opioids continue to be a mainstay in pain
management, this study addresses a pressing public health concern, urging a
reevaluation of opioid prescription practices and advocating for a proactive
stance on falls prevention in tandem with opioid therapy. The research marks a
significant step toward safeguarding the well-being of patients and fostering a
more nuanced understanding of the risks associated with prescription opioids
across diverse age groups.

Further reading: Age-Related Risk of Serious Fall Events and Opioid Analgesic Use. doi:10.1001/jamainternmed.2023.8154

Powered by WPeMatico

Deep learning-accelerated MRI improves detection of acute ischemic stroke: Study

Germany: Deep learning (DL)-accelerated brain MRI is four times faster, offers better image quality and diagnostic confidence and hence improves the detection of acute ischemic lesions compared to conventional MRI, a recent study published in Radiology has shown.

The researchers assert that the technique could translate to better patient care in that it could cut healthcare costs and improve imaging workflow.

Implementing this technique may be of great value, considering the increasing demand for medical examinations and increasing financial constraints placed on healthcare systems, the study stated.

DL-accelerated MRI can substantially reduce examination times. However, there is a lack of studies prospectively evaluating the diagnostic performance of DL-accelerated MRI reconstructions in acute suspected stroke. Therefore, Sebastian Altmann, University Medical Center Mainz, Germany, and colleagues investigated the interchangeability of DL-accelerated MRI with conventional MRI in patients with suspected acute ischemic stroke at 1.5 T.

For this purpose, they conducted a prospective study comprising 211 participants with suspected acute stroke who underwent clinically indicated MRI at 1.5 T between 2022 and 2023.

For each participant, conventional MRI (including T1-weighted, T2-weighted, T2*-weighted, T2 fluid-attenuated inversion-recovery, and diffusion-weighted imaging; 14 minutes 18 seconds) and DL-accelerated MRI (same sequences; 3 minutes 4 seconds), were conducted.

The primary endpoint was the e interchangeability between conventional and deep learning-accelerated MRI for detecting acute ischemic infarction. Secondary endpoints included interchangeability regarding the impacted vascular territory and clinically relevant secondary findings (eg, neoplasm, microbleeds).

The overall occurrence of acute ischemic stroke, clinically relevant secondary findings, affected vascular territory, diagnostic confidence, and overall image quality were evaluated by three readers. For acute ischemic lesions, size and signal intensities were assessed.

The interchangeability margin was chosen as 5%. For interrater reliability analysis and interrater agreement analysis, intraclass correlation coefficient and multi-rater Fleiss κ, respectively, were determined.

The researchers reported the following findings:

  • The study sample comprised 211 participants (mean age, 65 years); 123 male and 88 female). Acute ischemic stroke was confirmed in 79 participants.
  • Interchangeability was demonstrated for all primary and secondary endpoints. No individual equivalence indexes (IEIs) exceeded the interchangeability margin of 5% (IEI, −0.002).
  • Almost perfect interrater agreement was observed.
  • DL-accelerated MRI provided higher overall image quality and diagnostic confidence.
  • The signal properties of acute ischemic infarctions were similar in both techniques and demonstrated good to excellent interrater reliability (intraclass correlation coefficient, ≥0.8).

“Despite being four times faster, DL-accelerated brain MRI was interchangeable with conventional MRI for detecting acute ischemic lesions,” the researchers concluded.

Reference:

Altmann S, Grauhan NF, Brockstedt L, Kondova M, Schmidtmann I, Paul R, Clifford B, Feiweier T, Hosseini Z, Uphaus T, Groppa S, Brockmann MA, Othman AE. Ultrafast Brain MRI with Deep Learning Reconstruction for Suspected Acute Ischemic Stroke. Radiology. 2024 Feb;310(2):e231938. doi: 10.1148/radiol.231938. PMID: 38376403.

Powered by WPeMatico

Consumer Court dismisses complaint against Gastrointestinal Surgeon, orders Religare health insurance company to compensate

Ludhiana: Holding that insurance companies are required to be more liberal in their approach without being too technical, the District Consumer Disputes Redressal Commission in Ludhiana has dismissed a complaint against Gastrointestinal Surgeon and directed Religare Health Insurance Company to consider and reimburse a patient’s medical claim in accordance with the policy terms and conditions.

The case concerned Kumar who purchased a health insurance policy for his family from Religare Health Insurance Company Ltd., valid from 18.11.2017 to 17.11.2018, renewed until 17.11.2019. The complaint stems from the hospitalization of his son, Uppal, at Satguru Partap Singh Hospital on 05.02.2019 for appendicitis surgery.

Uppal underwent surgery on 06.02.2019 and was discharged on 09.02.2019. The complainant initiated the insurance claim process through OP1 (hospital), OP2 (Religare Health Insurance Company Ltd.), and OP3 (Claims Department, Religare Health Insurance Company Ltd.). However, the hospital, company and the department took four days to decide the insurance claim, causing distress. On 09.02.2019, they rejected the pre-authorization claim, citing a pre-existing condition of ‘ASTHMA.’ The complainant disputed this, asserting his son had no history of asthma. The discharge summary, prepared by OP4 (Gastrointestinal Surgeon), inaccurately mentioned “Known case of Asthma,” leading to the denial of the insurance claim. The complainant, dissatisfied, approached the hospital and the surgeon to rectify the inaccurate remarks but was refused.

The complainant moved the Commission and accused the company and the surgeon of deficiency in service, resulting in mental agony. He requested compensation of Rs.1,00,000/- along with interest, litigation expenses of Rs.20,000/-, and the insurance claim amount of Rs.97,417/-.

Upon notice, the company and the claim department appeared and filed a joint written statement, raising preliminary objections and challenging the complaint’s maintainability, alleging it was misleading and premature. They clarified that the complainant had only submitted a cashless request claim and had not filed any reimbursement claim with them. They pointed out that the complainant held a policy named “Care Floater”, covering him and his family members from 18.11.2017 to 17.11.2018 for a sum insured of Rs.5,00,000/-. The policy was subsequently renewed from 18.11.2018 to 17.11.2019.

The sequence of events unfolded when the insurance company and the department received a cashless request from Satguru Pratap Singh Hospital, Ludhiana, on 05.02.2019, for the admission of the insured, Uppal. The provisional diagnosis was Acute Appendicitis. In response, the Company sent a Query Letter dated 06.02.2019, requesting specific documents, including the exact duration and past history of the present ailment with the first consultation paper and all past treatment records, as well as pre-hospitalization OPD treatment records.

Upon receiving the hospital’s reply to the query, the Company issued an Authorization Letter on 06.02.2019. Subsequently, on 09.02.2019, a Deficiency Letter was sent, asking for complete indoor case papers, admission notes, history sheet, doctor’s notes, nursing notes, vital chart, and further details regarding the exact duration and past history of the present ailment, including the first consultation paper for asthma.

The joint response from the company and the claim department highlighted the communication and document exchange between the hospital and the insurance company, outlining the steps taken in processing the cashless request and addressing deficiencies. The complaint appeared to hinge on the rejection of the claim and the alleged pre-existing condition of asthma, a matter contested by the complainant.

The insurance company, after receiving documents from the hospital regarding a cashless claim, issued a Query Letter on 09.02.2019, requesting specific details, including the exact duration and past history of the present ailment with the first consultation paper and all past treatment records. Additionally, they sought the PAC Note related to pre-anesthesia checkup and treatment records regarding a lower respiratory tract infection (LRTI) from one year back.

Upon reviewing the documents and information gathered during the investigation, the insurance company emphasized that the insured was mentioned as a known case of Asthma in the Discharge Summary and Doctor’s progress notes, with a history of LRTI. Despite multiple Query Letters sent to the hospital, the company claimed not to have received adequate replies. Consequently, on 09.02.2019, the company rejected the complainant’s claim through a Claim Denial Letter, stating the non-submission of required necessary documents for past treatment details, which led to the inability to rule out the pre-existing nature of the ailment. The complainant was advised to file for reimbursement with all supportive documents.

On the merits of the case, the company and the department reiterated their earlier objections, denying any deficiency in service and urging the dismissal of the complaint.

In a separate written statement, the surgeon raised preliminary objections challenging the maintainability of the complaint. The doctor argued against the mis-joinder of necessary parties, asserting that the complaint was misconceived and an abuse of the process of law. Furthermore, he claimed that the complainant lacked the locus standi to file the complaint.

The surgeon emphasized that he had fulfilled his duties diligently and prudently in treating the patient with the utmost care. The patient, Uppal, was admitted to Satguru Partap Singh Hospital on 05.02.2019, diagnosed with acute appendicitis, and subsequently treated with Laparoscopic Appendectomy by OP4 on 06.02.2019. Throughout the treatment, the patient was clinically evaluated, thoroughly investigated, and post-operatively managed with antibiotics, analgesics, antacids, and other supportive measures. The patient’s condition improved, and he was discharged in a satisfactory condition on 09.02.2019.

The doctor further clarified that during the admission procedure, the complainant provided a history of the patient’s past ailment, specifically mentioning asthma. This information was duly recorded in the hospital’s records and reflected in the discharge summary provided to the complainant. The doctor asserted that the complainant did not object to this information at the time of discharge.

In response to queries raised by the company and the claim department regarding the patient’s treatment, the doctor provided a detailed written response on 09.02.2019, which was sent to both of them. The surgeon then claimed that neither the complainant nor the company and the department contacted him thereafter, and there was no reason for them to do so. The doctor insisted that neither OP1 (Satguru Partap Singh Hospital) nor he had any role or concern in the alleged claim refusal.

On the merits of the case, the surgeon reiterated the objections, denying any deficiency in service and requesting the dismissal of the complaint.

After considering the arguments from the parties, examining the complaint, affidavits, annexed documents, and written statements, the Commission noted that the complainant, covered by a cashless health insurance policy, had his son, Uppal, admitted to Satguru Partap Singh Hospital for appendicitis surgery. The surgery took place on 06.02.2019, and the discharge occurred on 09.02.2019, within the policy period.

During the hospitalization, a pre-authorization for a cashless claim was initiated on 06.02.2019, but the company and the claim department raised queries through Deficiency Letters. The cashless facility was ultimately declined on 09.02.2019 due to non-receipt of required documents, as stated in the Denial Letter. The complainant was advised to file a reimbursement claim with necessary documents.

In the Deficiency Letter dated 09.02.2019, the company and the department requested specific documents related to the ailment and medical history, particularly mentioning the possibility of asthma. Despite multiple requests and Deficiency Letters, the complainant did not file the claim with the company, leading to the rejection of the claim on 09.02.2019.

The complainant asserted a claim of Rs.1,73,087/- based on bills submitted as evidence. The Commission emphasized the need for insurance companies to adopt a more liberal approach in settling claims, citing the lack of significant assistance rendered to policyholders during claim settlements. The Commission suggested that insurance companies should be more considerate and less technical in their approach to claims. It noted;

“The Insurance companies do depute their officers/agent for procurement of business at the doorsteps of person(s) to be insured but at the time of settling the claims, the company’s officials or TPAs render little assistance to the policy holder. The insurance companies are required to be more liberal in their approach without being too technical.”

The Commission cited a 2022 Supreme Court judgment (Gurmel Singh Vs Branch Manager National Insurance Company Ltd.) emphasizing that insurance companies should not act too technically or arbitrarily while settling claims. The judgment stressed that insurers must not reject claims based on flimsy or technical reasons, especially when the insured faces challenges in providing certain documents. In light of this, the Commission directed the complainant to submit the required documents mentioned in Deficiency Letters to the company and the claim department. Following this, they were instructed to consider and reimburse the complainant’s claim in accordance with the policy’s terms and conditions after receiving the documents.

The complainant raised concerns against OP4, Dr. Singh, a Gastrointestinal Surgeon at Satguru Partap Singh Hospital, alleging that he incorrectly stated in the discharge summary that the patient was a “Known Case of Asthma,” leading to the rejection of the insurance claim by the company and the claim department. However, the doctor provided a certificate clarifying that the mention of asthma was based on the history provided by a distant relative, and the doctor had no role in processing the reimbursement claim. The certificate emphasized that the current illness (acute appendicitis) was unrelated to the past history of asthma. Consequently, the Commission deemed the complaint against the doctor as not maintainable and recommended its dismissal.

The complaint was partially allowed with a directive for the complainant to submit necessary documents, as per the Deficiency Letters, to the company and the claim department after receiving the order. Subsequently, they were instructed to consider and reimburse the complainant’s claim in accordance with the policy terms and conditions. No costswere  awarded. The complaint against the doctor was dismissed.

To view the original order, click on the link below:

Powered by WPeMatico